Teclistamab in Relapsed or Refractory Multiple Myeloma

To the Editor: Moreau and colleagues (August 11 issue)1 found that, in patients with relapsed or refractory myeloma, treatment with teclistamab, a T-cell–redirecting bispecific antibody that target...